{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "15865491", "DateCompleted": {"Year": "2005", "Month": "09", "Day": "29"}, "DateRevised": {"Year": "2022", "Month": "03", "Day": "21"}, "Article": {"Language": ["eng"], "ELocationID": [], "ArticleDate": [], "Journal": {"ISSN": "1075-5535", "JournalIssue": {"Volume": "11", "Issue": "2", "PubDate": {"Year": "2005", "Month": "Apr"}}, "Title": "Journal of alternative and complementary medicine (New York, N.Y.)", "ISOAbbreviation": "J Altern Complement Med"}, "ArticleTitle": "Restoration of normoxia by ozone therapy may control neoplastic growth: a review and a working hypothesis.", "Pagination": {"StartPage": "257", "EndPage": "265", "MedlinePgn": "257-65"}, "Abstract": {"AbstractText": ["In contrast to normal tissues, tumors thrive in hypoxic environments. This appears to be because they can metastasize and secrete angiopoietins for enhancing neoangiogenesis and further tumor spread. Thus, during chronic ischemia, normal tissues tend to die, while neoplasms tend to grow. During the past two decades, it has been shown in arteriopathic patients that ozonated autohemotherapy is therapeutically useful because it increases oxygen delivery in hypoxic tissues, leading to normoxia. Although several oxygenation approaches have been tested, none is able to restore normoxia permanently in patients with cancer. We postulate that a prolonged cycle of ozonated autohemotherapy may correct tumor hypoxia, lead to less aggressive tumor behavior, and represent a valid adjuvant during or after chemo- or radiotherapy. Moreover, it may re-equilibrate the chronic oxidative stress and reduce fatigue."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Physiology, University of Siena, Italy. bocci@unisi.it"}], "Identifier": [], "LastName": "Bocci", "ForeName": "Velio", "Initials": "V"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Larini", "ForeName": "Alessandra", "Initials": "A"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Micheli", "ForeName": "Vanna", "Initials": "V"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't", "Review"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "J Altern Complement Med", "NlmUniqueID": "9508124", "ISSNLinking": "1075-5535"}, "ChemicalList": [{"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "S88TT14065", "NameOfSubstance": "Oxygen"}], "MeshHeadingList": [{"QualifierName": ["drug effects"], "DescriptorName": "Cell Hypoxia"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["metabolism", "therapy"], "DescriptorName": "Neoplasms"}, {"QualifierName": ["metabolism"], "DescriptorName": "Oxygen"}, {"QualifierName": [], "DescriptorName": "Oxygen Consumption"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Ozone"}], "NumberOfReferences": "116"}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2005", "Month": "5", "Day": "4", "Hour": "9", "Minute": "0"}, {"Year": "2005", "Month": "9", "Day": "30", "Hour": "9", "Minute": "0"}, {"Year": "2005", "Month": "5", "Day": "4", "Hour": "9", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["15865491", "10.1089/acm.2005.11.257"]}}], "PubmedBookArticle": []}